Rib-X Pharmaceuticals makes appointment
This article was originally published in Scrip
Rib-X Pharmaceuticals, a US company focused on the discovery and development of antibiotics for the treatment of antibiotic-resistant infections, has appointed Dr George Milne executive chairman of the board of directors. Dr Milne succeeds Harry Penner, who has served as the company's board chairman since January 2001. Dr Milne joined Rib-X's board of directors in January 2004, and is a venture partner with Radius Ventures, a health and life sciences venture capital firm.